HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq:NTEC) today announced that it has received approval from Swissmedic, the Swiss Agency for Therapeutic Products, for the initiation of a Phase II human trial for NE-180. Clinical trial supplies have been shipped, and patient recruitment has commenced. NE-180 is a long-acting, GlycoPEGylated erythropoietin (EPO) being developed for the treatment of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy and for the treatment of anemia associated with chronic kidney disease, including patients on dialysis and patients not on dialysis.
